When Success Becomes the Problem: Rethinking Addiction in High-Performing Lives

There is a particular misconception about addiction that becomes especially problematic around successful people: that addiction should be visible.

It is assumed to involve deteriorating relationships, professional instability, financial problems or an inability to function. But for people operating at a high level, the reality can be considerably more complex.

A demanding career can provide structure. Achievement can provide identity. Travel can provide distraction. Financial resources can make consequences easier to absorb. And professional competence can make it possible to compensate for a problem for considerably longer than others might realise.

The result is a form of addiction that can remain largely invisible.

When functioning masks the problem

High-performing individuals often operate within environments where intensity is normalised.

Long working hours. Constant travel. High expectations. Irregular sleep. Performance pressure. Access to alcohol, stimulants or other substances. A social environment in which consumption is culturally accepted.

In such settings, the question is rarely simply whether someone uses a substance.

The more important questions are often: What function does it serve? What happens without it? And has the relationship with the substance changed?

A stimulant may initially be used to extend productivity or sustain demanding schedules. Alcohol may become a way to transition out of work or social performance. Other substances may provide temporary relief from anxiety, emotional exhaustion or an increasingly difficult internal state.

Over time, the original purpose can become secondary to the pattern itself.

This is one reason addiction can be particularly difficult to recognise in people who continue to perform exceptionally well.

The private cost of maintaining performance

High achievement can become part of the problem when performance itself becomes a form of psychological regulation.

The individual may not feel able to slow down. Rest can feel uncomfortable. Vulnerability can feel incompatible with professional identity. Emotional distress may be compartmentalised rather than addressed.

Substances can then become a private mechanism for managing states that are otherwise difficult to access or tolerate.

This does not mean that every high-performing person who uses substances has an addiction. Nor does it suggest that substance use is inherently pathological.

The distinction lies in the relationship: increasing loss of control, compulsive use, escalating consequences, unsuccessful attempts to reduce consumption, or reliance on a substance to regulate emotional or psychological states.

Recognising that distinction early can be important.

A changing conversation around psychedelic therapy

The field of psychedelic-assisted therapy is now beginning to investigate substance use disorders with considerably greater clinical specificity.

A 2026 randomized clinical trial published in JAMA Network Open examined psilocybin-assisted treatment for cocaine use disorder. Among 40 participants, a single 25 mg dose of psilocybin combined with manualised psychotherapy was associated with a greater proportion of cocaine-abstinent days, a higher likelihood of complete abstinence and a lower risk of cocaine lapse over 180 days compared with placebo plus the same psychotherapy. The authors emphasised that further research is warranted.

Separate 2026 research has also reported promising findings from a pilot trial investigating psilocybin-assisted treatment for smoking cessation.

These findings are significant, but they should not be interpreted as suggesting that psychedelics are a universal treatment for addiction.

They are not.

Psychedelic-assisted therapy remains an emerging clinical field. Outcomes depend on the substance, protocol, therapeutic framework, medical and psychological screening, preparation, support during the experience and integration afterwards.

Most importantly, treatment needs to address the underlying architecture of the addiction rather than simply the substance itself.

Looking beneath the behaviour

For some individuals, the central therapeutic question is not simply how to stop using.

It is why the substance became necessary in the first place.

What was it regulating?

What was it making possible?

What was it making easier not to feel?

And what would need to change for the person to no longer require that particular form of regulation?

This is where a sophisticated treatment approach becomes particularly important.

Addiction may coexist with depression, anxiety, unresolved trauma, chronic stress, burnout, relationship difficulties or profound disconnection from one's own values and needs. Treating the substance use without addressing these underlying factors may leave the deeper pattern intact.

A more discreet approach to seeking help

For someone accustomed to privacy, autonomy and high levels of personal responsibility, entering conventional addiction treatment can itself feel confronting.

The answer is not necessarily a more discreet version of the same treatment.

It is a more individualised one.

For appropriate candidates, psychedelic-assisted therapy may form one component of a broader therapeutic strategy, alongside psychological assessment, preparation, conventional psychotherapy, medical oversight, behavioural change and structured integration.

The objective is not simply abstinence.

It is the restoration of agency.

For someone whose professional identity has been built around performance, that can mean creating a life in which achievement no longer depends upon a substance — and where success is no longer purchased at the expense of psychological wellbeing.